Last reviewed · How we verify

NCT05867381: SAPIA

Using Indoor Air Filtration to Slow Atherothrombosis Progression in Adults With Ischemic Heart Disease History

Recruiting now NA Last updated 1 August 2025
What this trial tests

NA trial testing HEPA filtration in Air Pollution in 112 participants. Currently enrolling.

Timeline
11 July 2023
Primary endpoint
30 June 2027
30 June 2027

Quick facts

Lead sponsorUniversity of Southern California
PhaseNA
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationrandomized
Designcrossover
Maskingdouble
Primary purposeprevention
Enrollment112
Start date11 July 2023
Primary completion30 June 2027
Estimated completion30 June 2027
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

University of Southern California

Who can join

Adults 65 to 84, any sex, with Air Pollution or Atherosclerosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This double-blind, randomized, crossover trial aims to test the hypothesis that longer-term indoor air filtration intervention can slow atherothrombosis progression by reducing indoor fine particulate matter (PM2.5) exposure in adults with ischemic heart disease history.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Fine particulate matter levels and HEPA filtration in Los Angeles homes during a wildland-urban-interface fire.
    Chen R, Lin Y, Liao J, Qiu C, et al · · 2026 · PMID 41550628 · DOI 10.1038/s44407-025-00042-5

Verify or expand the search:

Other recruiting trials for Air Pollution

Currently open trials in the same condition.

Other University of Southern California trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05867381.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing